{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:13:55Z","timestamp":1791843235938,"version":"4.3.4"},"reference-count":111,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease and premature mortality worldwide. The World Health Organization and US Department of Health and Human Services have committed to eliminating HCV infection as a major public health threat by 2030, as defined by a 90% reduction in incidence of new HCV infections and 65% reduction in mortality from a 2015 baseline. To help to achieve HCV elimination, it will be necessary to increase HCV screening and increase uptake of HCV treatment, particularly within primary care, correctional, and substance use treatment settings. In this review, we provide strategies for healthcare providers to implement in their practice to enhance patients\u2019 completion of the steps of the HCV care cascade. Improving successful completion of each step of the cascade will help alleviate the burden of HCV infection and make the 2030 HCV elimination goals a reality.<\/jats:p>","DOI":"10.1093\/cid\/ciaf334","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:56:49Z","timestamp":1750233409000},"page":"e15-e26","source":"Crossref","is-referenced-by-count":8,"title":["State-of-the-Art Review: Hepatitis C"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-0600","authenticated-orcid":false,"suffix":"III","given":"Vincent","family":"Lo Re","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2136-7763","authenticated-orcid":false,"given":"Debika","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C","family":"Price","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Aronsohn","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago , Chicago Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-9666","authenticated-orcid":false,"given":"H Nina","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-2295","authenticated-orcid":false,"given":"Oluwaseun","family":"Falade-Nwulia","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matty","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Penn Presbyterian Medical Center , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Trooskin","sequence":"additional","affiliation":[{"name":"Executive Medical Officer, Mazzoni Center , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Torgersen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025091917043657900_ciaf334-B1","author":"World Health Organization"},{"key":"2025091917043657900_ciaf334-B2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/HEP.0000000000000927","article-title":"Estimating hepatitis C prevalence in the United States, 2017\u20132020","volume":"81","author":"Hall","year":"2024","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"2025091917043657900_ciaf334-B4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2025091917043657900_ciaf334-B5","author":"World Health Organization"},{"key":"2025091917043657900_ciaf334-B6","author":"US Department of Health and Human Services"},{"key":"2025091917043657900_ciaf334-B7","doi-asserted-by":"crossref","first-page":"e101554","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","volume":"9","author":"Yehia","year":"2014","journal-title":"PLoS One"},{"key":"2025091917043657900_ciaf334-B8","doi-asserted-by":"crossref","first-page":"ofac445","DOI":"10.1093\/ofid\/ofac445","article-title":"The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially insured population","volume":"9","author":"Ferrante","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025091917043657900_ciaf334-B9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jiph.2022.11.021","article-title":"Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: pathways to regain progress","volume":"16","author":"Blach","year":"2023","journal-title":"J Infect Public Health"},{"key":"2025091917043657900_ciaf334-B10","author":"Centers for Disease Control and Prevention"},{"key":"2025091917043657900_ciaf334-B11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix333","article-title":"Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States","volume":"65","author":"Canary","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B13","first-page":"CD012021","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025091917043657900_ciaf334-B14","author":"Centers for Disease Control and Prevention"},{"key":"2025091917043657900_ciaf334-B15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B16","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1002\/hep.510260711","article-title":"Epidemiology of hepatitis C","volume":"26","author":"Alter","year":"1997","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B17","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1016\/j.ijid.2010.03.019","article-title":"Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis","volume":"14","author":"Jafari","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2025091917043657900_ciaf334-B18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41575-020-00361-w","article-title":"Viral hepatitis and pregnancy","volume":"18","author":"Terrault","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","article-title":"Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis","volume":"6","author":"Jin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciaa645","article-title":"Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis","volume":"73","author":"Newsum","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(08)61116-2","article-title":"Acute hepatitis C","volume":"372","author":"Maheshwari","year":"2008","journal-title":"Lancet"},{"key":"2025091917043657900_ciaf334-B22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1537-2995.2005.04390.x","article-title":"Dynamics of viremia in early hepatitis C virus infection","volume":"45","author":"Glynn","year":"2005","journal-title":"Transfusion"},{"key":"2025091917043657900_ciaf334-B23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"2025091917043657900_ciaf334-B25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.510250344","article-title":"Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study","volume":"25","author":"Bruno","year":"1997","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091917043657900_ciaf334-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2025091917043657900_ciaf334-B28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement","volume":"323","author":"Owens","year":"2020","journal-title":"JAMA"},{"key":"2025091917043657900_ciaf334-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7204a1","article-title":"CDC recommendations for hepatitis C testing among perinatally exposed infants and children\u2014United States, 2023","volume":"72","author":"Panagiotakopoulos","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"2025091917043657900_ciaf334-B30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2468-1253(20)30365-4","article-title":"Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework","volume":"6","author":"Akiyama","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2019.02.008","article-title":"Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated","volume":"198","author":"Morris","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025091917043657900_ciaf334-B32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","article-title":"Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle","volume":"195","author":"Tsui","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025091917043657900_ciaf334-B33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/432478","article-title":"Humoral immune response in acute hepatitis C virus infection","volume":"41","author":"Netski","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0b013e32831940a3","article-title":"Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV","volume":"23","author":"Thomson","year":"2009","journal-title":"AIDS"},{"key":"2025091917043657900_ciaf334-B35","first-page":"362","article-title":"Testing for HCV infection: an update of guidance for clinicians and laboratorians","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091917043657900_ciaf334-B36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12879-017-2773-2","article-title":"Diagnostic accuracy of tests to detect hepatitis C antibody: a meta-analysis and review of the literature","volume":"17","author":"Tang","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025091917043657900_ciaf334-B37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737159.2017.1400385","article-title":"Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis","volume":"17","author":"Grebely","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"2025091917043657900_ciaf334-B38","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/hep.1840360709","article-title":"Use and interpretation of virological tests for hepatitis C","volume":"36","author":"Pawlotsky","year":"2002","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.15585\/mmwr.mm6518a2","article-title":"Identification and clinical management of persons with chronic hepatitis C virus infection\u2014Cherokee Nation, 2012\u20132015","volume":"65","author":"Mera","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091917043657900_ciaf334-B40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.15585\/mmwr.mm7228a2","article-title":"Updated operational guidance for implementing CDC's recommendations on testing for hepatitis C virus infection","volume":"72","author":"Cartwright","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091917043657900_ciaf334-B41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737159.2023.2292645","article-title":"We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?","volume":"24","author":"Grebely","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"key":"2025091917043657900_ciaf334-B42","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/jiac049","article-title":"Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of hepatitis C virus RNA: a systematic review","volume":"226","author":"Catlett","year":"2022","journal-title":"J Infect Dis"},{"key":"2025091917043657900_ciaf334-B43","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis","volume":"7","author":"Cunningham","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","article-title":"Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis","volume":"8","author":"Trickey","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B45","author":"US Centers for Disease Control and Prevention. National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis"},{"key":"2025091917043657900_ciaf334-B46","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/cid\/ciad503","article-title":"The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination","volume":"78","author":"Kapadia","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B47","author":"American Association for the Study of Liver Diseases\/Infectious Diseases Society of America"},{"key":"2025091917043657900_ciaf334-B48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/flgastro-2022-102373","article-title":"Hepatitis C: recent advances and practical management","volume":"14","author":"O' Kane","year":"2023","journal-title":"Frontline Gastroenterol"},{"key":"2025091917043657900_ciaf334-B49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection","volume":"75","author":"Matthews","year":"2021","journal-title":"J Hepatol"},{"key":"2025091917043657900_ciaf334-B50","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1093\/cid\/ciad344","article-title":"Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review","volume":"77","author":"Martinello","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B51","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57 Suppl 2","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B52","doi-asserted-by":"crossref","first-page":"877585","DOI":"10.3389\/fpubh.2022.877585","article-title":"Interventions to improve uptake of direct-acting antivirals for hepatitis C virus in priority populations: a systematic review","volume":"10","author":"Ortiz-Paredes","year":"2022","journal-title":"Front Public Health"},{"key":"2025091917043657900_ciaf334-B53","doi-asserted-by":"crossref","first-page":"108525","DOI":"10.1016\/j.drugalcdep.2021.108525","article-title":"Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington","volume":"220","author":"Corcorran","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025091917043657900_ciaf334-B54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.amepre.2021.04.013","article-title":"Cascade of hepatitis C virus care among patients with substance use disorders","volume":"61","author":"Jiang","year":"2021","journal-title":"Am J Prev Med"},{"key":"2025091917043657900_ciaf334-B55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12954-020-00409-9","article-title":"A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South","volume":"17","author":"Sherbuk","year":"2020","journal-title":"Harm Reduct J"},{"key":"2025091917043657900_ciaf334-B56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","article-title":"High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic","volume":"47","author":"Norton","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025091917043657900_ciaf334-B57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/M18-2124","article-title":"Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data","volume":"170","author":"Schranz","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025091917043657900_ciaf334-B59","doi-asserted-by":"crossref","first-page":"e0242165","DOI":"10.1371\/journal.pone.0242165","article-title":"Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018","volume":"15","author":"Capizzi","year":"2020","journal-title":"PLoS One"},{"key":"2025091917043657900_ciaf334-B60","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/ciad711","article-title":"Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): a stepped wedge cluster randomized trial","volume":"78","author":"Midgard","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B61","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1007\/s11606-023-08386-y","article-title":"Inpatient hepatitis C treatment coordination and initiation for patients who inject drugs","volume":"38","author":"McCrary","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2025091917043657900_ciaf334-B62","doi-asserted-by":"crossref","first-page":"ofaf237","DOI":"10.1093\/ofid\/ofaf237","article-title":"Hepatitis C treatment initiation during hospitalization for people who use drugs: a narrative review of the literature","volume":"12","author":"Denkins","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025091917043657900_ciaf334-B63","doi-asserted-by":"crossref","first-page":"ofac225","DOI":"10.1093\/ofid\/ofac225","article-title":"Rapid treatment initiation for hepatitis C in young people who inject drugs: the seek, test, and rapid treatment randomized trial","volume":"9","author":"Eckhardt","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025091917043657900_ciaf334-B64","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"key":"2025091917043657900_ciaf334-B65","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11606-019-05599-y","article-title":"Assessing and expanding the evidence base for project ECHO and ECHO-like models: findings of a technical expert panel","volume":"35","author":"Faherty","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2025091917043657900_ciaf334-B66","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep4.1340","article-title":"Telemedicine: an evolving field in hepatology","volume":"3","author":"Piao","year":"2019","journal-title":"Hepatol Commun"},{"key":"2025091917043657900_ciaf334-B67","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1731","article-title":"Key elements on the pathway to HCV elimination: lessons learned from the AASLD HCV Special Interest Group 2020","volume":"5","author":"Feld","year":"2021","journal-title":"Hepatol Commun"},{"key":"2025091917043657900_ciaf334-B68","doi-asserted-by":"crossref","first-page":"108438","DOI":"10.1016\/j.jsat.2021.108438","article-title":"Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings","volume":"131","author":"Ngo","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2025091917043657900_ciaf334-B69","doi-asserted-by":"crossref","first-page":"ofaf211","DOI":"10.1093\/ofid\/ofaf211","article-title":"Approaches to offering hepatitis C treatment at syringe services programs in the United States: a scoping review","volume":"12","author":"Yoder","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025091917043657900_ciaf334-B70","doi-asserted-by":"crossref","first-page":"e021443","DOI":"10.1136\/bmjopen-2017-021443","article-title":"Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial","volume":"8","author":"Radley","year":"2018","journal-title":"BMJ Open"},{"key":"2025091917043657900_ciaf334-B71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/cid\/ciy899","article-title":"Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone","volume":"69","author":"Talal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B72","doi-asserted-by":"crossref","first-page":"e2338792","DOI":"10.1001\/jamanetworkopen.2023.38792","article-title":"Community-based point-of-diagnosis hepatitis C treatment for marginalized populations: a nonrandomized controlled trial","volume":"6","author":"Morris","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025091917043657900_ciaf334-B73","first-page":"100648","article-title":"Implementation of a mobile health clinic framework for hepatitis C virus screening and treatment: a descriptive study","volume":"29","author":"Rennert","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"2025091917043657900_ciaf334-B74","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/v16121882","article-title":"Findings from a project which established hepatitis C point-of-care testing and linkage to care at a homelessness service in Adelaide, Australia, 2021\u20132022","volume":"16","author":"McCartney","year":"2024","journal-title":"Viruses"},{"key":"2025091917043657900_ciaf334-B75","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/jvh.13343","article-title":"Determinants of stigma among patients with hepatitis C virus infection","volume":"27","author":"Saine","year":"2020","journal-title":"J Viral Hepat"},{"key":"2025091917043657900_ciaf334-B76","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials","volume":"28","author":"Gane","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025091917043657900_ciaf334-B77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B78","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B79","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11901-017-0343-0","article-title":"Alcohol consumption in concomitant liver disease: how much is too much?","volume":"16","author":"Hagstr\u00f6m","year":"2017","journal-title":"Curr Hepatol Rep"},{"key":"2025091917043657900_ciaf334-B80","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/apt.12265","article-title":"Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C","volume":"37","author":"Younossi","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2025091917043657900_ciaf334-B81","doi-asserted-by":"crossref","first-page":"e2335715","DOI":"10.1001\/jamanetworkopen.2023.35715","article-title":"Alcohol use and sustained virologic response to hepatitis C virus direct-acting antiviral therapy","volume":"6","author":"Cartwright","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025091917043657900_ciaf334-B82","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B83","doi-asserted-by":"crossref","first-page":"875","DOI":"10.15585\/mmwr.mm7024a2","article-title":"Hepatitis A virus infections among men who have sex with men\u2014eight U.S. states, 2017\u20132018","volume":"70","author":"Foster","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091917043657900_ciaf334-B84","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B85","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B86","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B87","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B88","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/BF01308607","article-title":"Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland","volume":"38","author":"Froehlich","year":"1993","journal-title":"Dig Dis Sci"},{"key":"2025091917043657900_ciaf334-B89","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/HEP.0000000000000842","article-title":"Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline","volume":"81","author":"Patel","year":"2025","journal-title":"Hepatology"},{"key":"2025091917043657900_ciaf334-B90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/23744235.2023.2178670","article-title":"Delays in fibrosis staging reduce the likelihood of achieving hepatitis C treatment and cure","volume":"55","author":"Jones","year":"2023","journal-title":"Infect Dis (Lond)"},{"key":"2025091917043657900_ciaf334-B91","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review","volume":"329","author":"Tapper","year":"2023","journal-title":"JAMA"},{"key":"2025091917043657900_ciaf334-B92","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jhep.2021.07.021","article-title":"Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation","volume":"75","author":"Torgersen","year":"2021","journal-title":"J Hepatol"},{"key":"2025091917043657900_ciaf334-B93","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MD.0b013e31821a5a76","article-title":"Factors predicting mortality in invasive pneumococcal disease in adults in Alberta","volume":"90","author":"Marrie","year":"2011","journal-title":"Medicine"},{"key":"2025091917043657900_ciaf334-B94","first-page":"405","article-title":"Vibrio vulnificus infections associated with raw oyster consumption\u2014Florida, 1981\u20131992","volume":"42","author":"Centers for Disease Control and Prevention","year":"1993","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091917043657900_ciaf334-B95","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025091917043657900_ciaf334-B96","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"2025091917043657900_ciaf334-B97","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/cid\/ciae595","article-title":"Sofosbuvir\/velpatasvir pharmacokinetics, safety, and efficacy in pregnant people with hepatitis C virus","volume":"80","author":"Chappell","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B98","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B99","doi-asserted-by":"crossref","first-page":"13596535231189643","DOI":"10.1177\/13596535231189643","article-title":"Hepatitis C virus\/hepatitis B virus coinfection: current prospectives","volume":"28","author":"Maqsood","year":"2023","journal-title":"Antivir Ther"},{"key":"2025091917043657900_ciaf334-B100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025091917043657900_ciaf334-B101","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2023.12.020","article-title":"Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: the HERO study","volume":"80","author":"Heo","year":"2024","journal-title":"J Hepatol"},{"key":"2025091917043657900_ciaf334-B102","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B103","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","article-title":"Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis","volume":"67","author":"Cacoub","year":"2018","journal-title":"Gut"},{"key":"2025091917043657900_ciaf334-B104","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2015.07.035","article-title":"Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection","volume":"14","author":"Gerber","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025091917043657900_ciaf334-B105","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"2025091917043657900_ciaf334-B106","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciae297","article-title":"Hepatitis C virus reinfection among men who have sex with men with HIV in New York City","volume":"79","author":"Fierer","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B107","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"2025091917043657900_ciaf334-B108","doi-asserted-by":"crossref","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025091917043657900_ciaf334-B109","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/jvh.13549","article-title":"Real world SOF\/VEL\/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy","volume":"28","author":"Smith","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025091917043657900_ciaf334-B110","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","volume":"157","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"key":"2025091917043657900_ciaf334-B111","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"Wyles","year":"2019","journal-title":"J Hepatol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/e15\/64274611\/ciaf334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/e15\/64274611\/ciaf334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:05:08Z","timestamp":1758315908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/2\/e15\/8254423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":111,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf334","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,15]]},"published":{"date-parts":[[2025,4,23]]}}}